| Use of taurolidine to treat tumors -> Monitor Keywords |
|
|
 
Use of taurolidine to treat tumorsUse of taurolidine to treat tumors description/claimsThe Patent Description & Claims data below is from USPTO Patent Application 20090163479, Use of taurolidine to treat tumors. Brief Patent Description - Full Patent Description - Patent Application Claims
This application claims the benefit from provisional application Ser. No. 60/169,122, which was filed on Dec. 6, 1999, provisional application Ser. No. 60/169,127, which was filed on Dec. 6, 1999, and provisional application Ser. No. 60/169,128, which was filed on Dec. 6, 1999. The invention relates to cancer therapy. Despite advances in the identification of chemotherapeutic agents for inhibiting the growth of cancer cell, cancer remains a formidable disease with a high mortality rate. A significant problem of chemotherapeutic agents is low specificity. Many anticancer agents do not adequately distinguish normal cells from cancer cells. As a result, they often carry undesirable serious side effects. The invention provides a method of inhibiting tumor growth in a mammal with few or no deleterious side effects. The method is carried out by administering to the mammal composition containing an active methylol-containing compound. The compound is administered to directly contact a tumor cell at a dose sufficient to induce cell death by apoptosis. Preferably the compound is administered in a manner and at a dose which preferentially induces apoptotic death compared to necrotic death. By “methylol containing compound” is meant a compound which contains or is capable of producing a methylol molecule in an aqueous environment. An aqueous environment includes conditions encountered following administration to a mammal, i.e., under physiological conditions. A molecule of taurolidine produces three methylol molecules, whereas a molecule of taurultam produces one methylol species. A method of treating an autologous tumor, e.g., a tumor of the central nervous system (CNS), is carried out by administering to a mammal, e.g., a human patient, a methylol-containing compound. The compound is administered systemically, e.g., orally or intravenously, or infused directly into the brain or cerebrospinal fluid. An erodible or resorbable solid matrix such as a wafer or sponge is implanted directly into brain tissue. Preferably, the tumor is a glioma, astrocytoma, neuroblastoma, or CNS metastasis from a non-CNS primary tumor. The methylol-containing compound is characterized as having a R—CH2—OH group in which R is an alkyl, aryl or hetero group. The invention also includes compounds capable of producing or being converted into a compound containing a R—CH2—OH structure. Preferably the compound is taurolidine, taurultam, or a derivative thereof (Tables 1, 2). R is an alkyl, aryl, hydrogen or hetero group or atom.
Alternatively, the compound is a taurinamide derivative, e.g., a compound shown in Table 3; or a urea derivative, e.g., a compound shown in Table 4.
| ||
How KEYWORD MONITOR works... a FREE service from FreshPatents
